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In the clinical field, insulin has been used for treatment of dia-
betes. However, insulin often shows low physicochemical
stability, adsorption onto tubes and enzymatic degradation in
injection site or blood. Previously, we demonstrated that
cyclodextrins (CyDs), especially branched β-CyDs, improve the
pharmaceutical properties of insulin through complexation with
its aromatic residues. However, little has been reported on the
insulin conjugate with branched β-CyD. In the present study,
to improve the pharmaceutical properties of insulin, we newly
prepared 6-Ο-α-(4-Ο-α-D-glucuronyl)-D-glucosyl-β-CyD (GUG-
β-CyD) conjugate with insulin, and evaluated its thermal or
enzymatic stability and adsorption onto glass or polypropyl-
ene tube [1]. To prepare GUG-β-CyD-insulin conjugate, insulin
and activated GUG-β-CyD were reacted in DMF/water (pH 10)
for 10 min at room temperature (Fig. 1A). Preparation of GUG-
β-CyD-insulin conjugate was confirmed by a MALDI-TOF mass
spectrum.An inclusion ability of CyD in GUG-β-CyD-insulin con-
jugate was examined by measuring fluorescence spectrum in
the presence of 2-p-toluidinylnaphthalene-6-sulfonate(TNS).The
conformation of insulin in GUG-β-CyD-insulin conjugate was
confirmed by a circular dichroism (CD) spectrum. In the ad-
sorption study, GUG-β-CyD-insulin conjugate solution was
placed in a glass or a polypropylene tube. After standing the
sample for 2 h at 25 °C, the absorbance of the solution was
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measured by a spectrophotometer (280 nm).The thermal or en-
zymatic stability of GUG-β-CyD-insulin conjugate was evaluated
after heating at 50 °C or incubation with trypsin at 37 °C, and
then the intact insulin level was measured by a spectropho-
tometer or HPLC.
A new peak derived from GUG-β-CyD-insulin conjugate was
observed in a MALDI-TOF mass spectrum.The fluorescence in-
tensity of TNS markedly increased in the presence of GUG-β-
CyD-insulin conjugate, suggesting that CyD in GUG-β-CyD-
insulin conjugate possesses inclusion ability. Also, according
to the result of a CD spectrum, conformation of insulin in the
conjugate was retained. GUG-β-CyD-insulin conjugate ad-
sorbed onto a glass and a polypropylene tube only very slightly.
Thermal and enzymatic stability of GUG-β-CyD-insulin con-
jugate was markedly improved, compared to that of insulin
alone or the mixture (Fig. 1B,C).
Consequently, these results suggest that the conjugation with
GUG-β-CyD could be useful for improvement of some phar-
maceutical properties of insulin.
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Fig. 1 – (A) Preparation pathway of GUG-β-CyD-insulin conjugate and its (B) enzymatic and (C) thermal stability. Each value
represents the mean ± S.E.M. of 3–6 experiments. *P < 0.05 versus insulin. †P < 0.05 versus insulin + GUG-β-CyD mixture.
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